ERBB2 and breast cancer: Both demonstrated that patients with HER2+ BC who underwent trastuzumab treatment experienced a significantly longer median time to BCBM than patients who did not, with a gain of 11 months (HR 2.13, 95% CI 1.51–3.00, p = 0.28) (43, 44).